Search clinical trials for: LEO 80185 vehicle

Total 3341 results

LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 80185 Gel

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects

Skin and Connective Tissue Diseases

Japan
LEO Pharma

Completed

LEO 124249 Ointment in the Treatment of Alopecia Areata

Alopecia Areata

United States
LEO Pharma

Completed

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Scalp Psoriasis

United States
LEO Pharma

Completed

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

Actinic Keratosis

United States
LEO Pharma

Terminated

Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.

Atopic Dermatitis

Germany
LEO Pharma

Completed

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Germany, Denmark
LEO Pharma

Completed

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
LEO Pharma

Completed

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

Hand Eczema

Germany
LEO Pharma

Completed

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Australia
LEO Pharma

Terminated

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Discoid Lupus Erythematosus

United States, France, Germany, Denmark
LEO Pharma

Completed

An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

Atopic Dermatitis

Germany
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Psoriasis Vulgaris

United States, Canada, Germany, United Kingdom, France, Poland
LEO Pharma

Terminated

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

Alopecia Areata

Denmark
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis

Inverse Psoriasis

Germany
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma
CMIC Co, Ltd. Japan

Completed

LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects

Psoriasis Vulgaris

United States, Canada, United Kingdom, Germany, Romania, France, Poland
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (DELTA 2)

Chronic Hand Eczema

Belgium, Canada, Denmark, Germany, Netherlands, Poland, Spain
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1)

Chronic Hand Eczema

Canada, France, Germany, Italy, Poland, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
LEO Pharma

Completed

Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Scalp Psoriasis

Canada, United Kingdom, France
LEO Pharma

Completed

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Frontal Fibrosing Alopecia

United States
LEO Pharma

Completed

Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Psoriasis Vulgaris

Japan
LEO Pharma

Terminated

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

Actinic Keratosis | Squamous Cell Carcinoma

United States, Spain, Canada, Germany, France, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100

Psoriasis Vulgaris

France
LEO Pharma

Completed

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

France
Neo Medical SA
ConfinisCPM

Active, not recruiting

PMCF Neo Pedicle Screw and Cage Systems

Trauma | Degenerative Disc Disease | Spinal Stenosis | Spondylolisthesis | Spinal Tumor | Pseudoarthrosis of Spine

Germany, Spain
MedImmune LLC

Completed

Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, Poland
LEO Pharma

Completed

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

Healthy

United Kingdom
LEO Pharma

Completed

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

A Vasoconstriction Study With LEO 90100

Psoriasis Vulgaris

France
LEO Pharma

Completed

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

Atopic Dermatitis

Netherlands
MedImmune LLC
Cambridge Antibody Technology

Terminated

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

Leukemia, Lymphoma, Chronic Lymphocytic | Leukemia, Prolymphocytic Leukemia, Small | Lymphocytic Lymphoma, Moxetumomab Pasudotox

United States, Poland
LEO Pharma

Completed

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Actinic Keratosis

United States
Cairo University

Unknown

Clinical Evaluation of Fracture Resistance and Color Changes of Laminate Veneer With Gull Wing Preparation

Discolored Teeth
LEO Pharma

Completed

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Actinic Keratosis

Canada, United States
JW Pharmaceutical
LEO Pharma

Completed

Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria

Cholinergic Urticaria

Germany
LEO Pharma

Completed

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Germany, Poland
LEO Pharma

Completed

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Atopic Dermatitis

United States
LEO Pharma

Completed

A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products

Psoriasis Vulgaris

France

3

Subscribe